Trimethoprim-sulfamethoxazole revisited

Archives of Internal Medicine

Volumn 163, Issue 4, 2003, Pages 402-410

  Masters, Philip A ^a   O'Bryan, Thomas A ^a   Zurlo, John ^a   Miller, Debra Q ^a   Joshi, Nirmal ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COTRIMOXAZOLE;

AGRANULOCYTOSIS; ANEMIA; ANOREXIA; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; ASEPTIC MENINGITIS; BACTERIAL INFECTION; COST EFFECTIVENESS ANALYSIS; DELIRIUM; DIARRHEA; DOSE RESPONSE; DRUG ABSORPTION; DRUG COST; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; ERYTHEMA; ERYTHEMA MULTIFORME; GASTROINTESTINAL INFECTION; GASTROINTESTINAL SYMPTOM; GLOSSITIS; GRANULOCYTOPENIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERKALEMIA; HYPERSENSITIVITY REACTION; HYPONATREMIA; LIVER TOXICITY; NAUSEA; OPPORTUNISTIC INFECTION; PHOTOSENSITIVITY DISORDER; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PSYCHOSIS; PURPURA; RASH; RESPIRATORY TRACT INFECTION; REVIEW; RHABDOMYOLYSIS; SKIN INFECTION; SKIN MANIFESTATION; STEVENS JOHNSON SYNDROME; STOMATITIS; THROMBOCYTOPENIA; TOXIC EPIDERMAL NECROLYSIS; TREMOR; UREMIA; URINARY TRACT INFECTION; URTICARIA; VOMITING;

ANTI-INFECTIVE AGENTS; BACTERIAL INFECTIONS; DRUG INTERACTIONS; DRUG RESISTANCE, MICROBIAL; HUMANS; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION;

EID: 0037463683     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.163.4.402     Document Type: Review

References (134)

1. Gonzales R, Bartlett JG, Besser RE, et al. Principles of appropriate antibiotic use for treatment of acute respiratory tract infections in adults: background, specific aims, and methods. Ann Intern Med. 2001;134:479-486.
2. Bushby SRM, Hitchings GH. Trimethoprim, a sulphonamide potentiator. Br J Pharmacol. 1968;33:72-90.
3. Bushby SRM. Trimethoprim-sulfamethoxazole: in vitro microbiological aspects. J Infect Dis. 1973;128(suppl):S442-S462.
4. Darrell JH, Garrod LP, Waterworth PM. Trimethoprim: laboratory and clinical studies. J Clin Pathol. 1968;21:202-209.
5. Brumfitt W, Hamilton-Miller JM, Havard CW, Tansley H. Trimethoprim alone compared to cotrimoxazole in lower respiratory infections: pharmacokinetics and clinical effectiveness. Scand J Infect Dis. 1985;17:99-105.
6. Lacey RW, Lord VL, Gunasekera HK, Leiberman PJ, Luxton DE. Comparison of trimethoprim alone with trimethoprim-sulphamethoxazole in the treatment of respiratory and urinary infections with particular reference to selection of trimethoprim resistance. Lancet. 1980;1:1270-1273.
7. Rubin R, Swartz M. Trimethoprim-sulfamethoxazole. N Engl J Med. 1980;303:426-432.
8. Howe R, Spencer R. Cotrimoxazole: rationale for re-examining its indications for use. Drug Saf. 1996;14:213-218.
9. Brumfitt W, Pursell R. Trimethoprim-sulfamethoxazole in the treatment of bacteriuria in women. J Infect Dis. 1973;128(suppl):657-665.
10. Smilack JD. Trimethoprim-sulfamethoxazole. Mayo Clin Proc. 1999;74:730-734.
11. Wormser GP, Keusch GT. Trimethoprim-sulfamethoxazole in the United States. Ann Intern Med. 1979;91:420-429.
12. O'Reilly R, Motley C. Racemic warfarin and trimethoprim-sulfamethoxazole interaction in humans. Ann Intern Med. 1979;91:34-36.
13. O'Reilly R. Stereoselective interaction of trimethoprim-sulfamethoxazole with the separated enantiomorphs of racemic warfarin in man. N Engl J Med. 1980;302:33-35.
14. van Meerten E, Verweij J, Schellens J. Antineoplastic agents: drug interactions of clinical significance. Drug Saf. 1995;12:168-182.
15. Tett S, Triggs E. Use of methotrexate in older patients: a risk-benefit assessment. Drugs Aging. 1996;9:458-471.
16. Hansen JM, Kampmann JP, Siersbaek-Nielsen K, et al. The effect of different sulfonamides on phenytoin metabolism in man. Acta Med Scand Suppl. 1979;624:106-110.
17. Brumfitt W, Hamilton-Miller J. Limitations of and indications for the use of co-trimoxazole. J Chemother. 1994;6:3-11.
18. Johnson JF, Dobmeier ME. Symptomatic hypoglycemia secondary to a glipizide-trimethoprim/sulfamethoxazole drug interaction. DICP. 1990; 24:250-251.
19. Chan J, Cockram C, Critchley J. Drug-induced disorders of glucose metabolism: mechanisms and management. Drug Saf 1996;15:135-157.
20. Kosoglou T, Rocci M, Vlasses P. Trimethoprim alters the disposition of procainamide and N-acetylprocainamide. Clin Pharmacol Ther. 1988; 44:467-477.
21. Abramowicz M, ed. Oral contraceptives. Med Lett Drugs Ther. 2000;42:42-44.
22. Lawson D, Jick H. Adverse reactions to cotrimoxazole in hospitalized medical patients. Am J Med Sci. 1978;275:53-57.
23. Lawson D, MacDonald S. Antibacterial therapy in general medical wards. Postgrad Med J. 1977;53:306-309.
24. Jick H. Adverse reactions to trimethoprim-sulfamethoxazole in hospitalized patients. Rev Infect Dis. 1982;4:426-428.
25. Ducharme M, Smythe M, Strohs G. Drug-induced alterations in serum creatinine concentrations. Ann Pharmacother. 1993;27:622-633.
26. Choi MJ, Fernandez PC, Patnaik A, et al. Brief report: trimethoprim-induced hyperkalemia in a patient with AIDS. N Engl J Med. 1993;328:703-706.
27. Velazquez H, Perazella M, Wright F, Ellison D. Renal mechanism of trimethoprim-induced hyperkalemia. Ann Intern Med. 1993;119:296-301.
28. Marinella M. Trimethoprim-induced hyperkalemia: an analysis of reported cases. Gerontology. 1999;45:209-212.
29. Jick H, Derby L. A large population-based follow-up study of trimethoprim-sulphamethoxazole, trimethoprim, and cephalexin for uncommon serious drug toxicity. Pharmacotherapy. 1995;15:428-432.
30. Ambramowicz M, ed. Drugs that may cause psychiatric symptoms. Med Lett Drugs Ther. 2000; 44:59-62.
31. McCue JD, Zandt JR. Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole. Am J Med. 1991;90: 528-529.
32. Brumfitt W, Pursell R. Double-blind trial to compare ampicillin, cephalexin, co-trimoxazole and trimethoprim in treatment of urinary infections. BMJ. 1972;2:673-676.
33. Frisch JM. Clinical experience with adverse reactions to trimethoprim-sulfamethoxazole. J Infect Dis. 1973;128(suppl):S607-S611.
34. Gleckman R, Alvarez S, Joubert DW. Drug therapy reviews: trimethoprim-sulfamethoxazole. Am J Hosp Pharm. 1979;36:893-906.
35. Boye NP, Gaustad P. Double-blind comparative study of ofloxacin and trimethoprim-sulfamethoxazole in the treatment of patients with acute exacerbations of chronic bronchitis and chronic obstructive lung disease. Infection. 1991;19(suppl 7):S388-S390.
36. Grubbs NC, Schultz HJ, Henry NK, Ilstrup DM, Muller SM, Wilson WR. Ciprofloxacin versus trimethoprim-sulfamethoxazole: treatment of community-acquired urinary tract infections in a prospective, controlled, double-blind comparison. Mayo Clin Proc. 1992;67:1163-1168.
37. Heck J, Staneck JL, Cohen MB, et al. Prevention of travelers' diarrhea: ciprofloxacin versus trimethoprim/sulfamethoxazole in adult volunteers working in Latin America and the Caribbean. J Travel Med. 1994;1:136-142.
38. Roujeau J, Kelly J, Naldi L, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med. 1995; 333:1600-1607.
39. Egan CA, Grant WJ, Morris SE, Saffle JR, Zone JJ. Plasmapheresis as an adjunct treatment in toxic epidermal necrolysis. J Am Acad Dermatol. 1999;40:458-461.
40. Berglund F, Killander J, Pompeius R. Effect of trimethoprim-sulfamethoxazole on the renal excretion of creatinine in man. J Urol. 1975;114: 802-808.
41. Bye A. Drug interference with creatinine assay. Clin Chem. 1976;22:283-284.
42. Shouval D, Ligumsky M, Ben-Ishay D. Effect of co-trimoxazole on normal creatinine clearance. Lancet. 1978;1:244-245.
43. Burchall JJ, Hitchings GH. Inhibitor binding analysis of dihydrofolate reductases from various species. Mol Pharmacol. 1965;1:126-136.
44. Kovacs JA, Hiemenz JW, Macher AM, et al. Pneumocystis carinii pneumonia: a comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies. Ann Intern Med. 1984;100:663-671.
45. Sattler FR, Cowan R, Nielsen DM, Ruskin J. Trimethoprim-sulfamethoxazole compared with pentamidine for treatment of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome: a prospective, noncrossover study. Ann Intern Med. 1988;109:280-287.
46. Klein NC, Duncanson FP, Lenox TH, et al. Trimethoprim-sulfamethoxazole versus pentamidine for Pneumocystis carinii pneumonia in AIDS patients: results of a large prospective randomized treatment trial. AIDS. 1992;6:301-305.
47. Medina I, Mills J, Leoung G, et al. Oral therapy for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome: a controlled trial of trimethoprim-sulfamethoxazole versus trimethoprim-dapsone. N Engl J Med. 1990; 323:776-782.
48. Jung AC, Paauw DS, Management of adverse reactions to trimethoprim-sulfamethoxazole in human immunodeficiency virus-infected patients. Arch Intern Med. 1994;154:2402-2406.
49. Hughes WT, LaFon SW, Scott JD, Masur H. Adverse events associated with trimethoprim-sulfamethoxazole and atovaquone during the treatment of AIDS-related Pneumocystis carinii pneumonia. J Infect Dis. 1995;171:1295-1301.
50. Porteous DM, Berger TG. Severe cutaneous drug reactions (Stevens-Johnson syndrome and toxic epidermal necrolysis) in human immunodeficiency virus infection. Arch Dermatol. 1991;127: 740-741.
51. Greenberg S, Reiser IW, Chou SY. Hyperkalemia with high-dose trimethoprim-sulfamethoxazole therapy. Am J Kidney Dis. 1993;22:603-606.
52. Aboulafia DM. Tremors associated with trimethoprim-sulfamethoxazole therapy in a patient with AIDS: case report and review. Clin Infect Dis. 1996;22:598-600.
53. Jurado R, Carpenter SL, Rimland D. Case reports: trimethoprim-sulfamethoxazole -induced meningitis in patients with HIV infection. Am J Med Sci. 1996;312:27-29.
54. Singer SJ, Racoosin JA, Viraraghavan R. Rhabdomyolysis in human immunodeficiency virus-positive patients taking trimethoprim-sulfamethoxazole. Clin Infect Dis. 1998;26:233-234.
55. Shafer RW, Seitzman PA, Tapper ML. Successful prophylaxis of Pneumocystis carinii pneumonia with trimethoprim-sulfamethoxazole in AIDS patients with previous allergic reactions. J Acquir Immune Defic Syndr. 1989;2:389-393.
56. Gluckstein D, Ruskin J. Rapid oral desensitization to trimethoprim-sulfamethoxazole (TMP-SMZ): use in prophylaxis for Pneumocystis carinii pneumonia in patients with AIDS who were previously intolerant to TMP-SMZ. Clin Infect Dis. 1995;20:849-853.
57. Gompels MM, Simpson N, Snow M, Spickett G, Ong E. Desensitization to co-trimoxazole (trimethoprim-sulphamethoxazole) in HIV-infected patients: is patch testing a useful predictor of reaction? J Infect. 1999;38:111-115.
58. Bach MC, Finland M, Gold O, Wilcox C. Susceptibility of recently isolated pathogenic bacteria to trimethoprim and sulfamethoxazole separately and combined. J Infect Dis. 1973;128 (suppl):S508-S533.
59. Huovinen P. Resistance to trimethoprim-sulfamethoxazole. Clin Infect Dis. 2001;32:1608-1614.
60. Huovinen P, Sundström L, Swedeberg G, Sköld O. Trimethoprim and sulfonamide resistance. Antimicrob Agents Chemother. 1995;39:279-289.
61. Stamm WE, Hooten TM. Management of urinary tract infections in adults. N Engl J Med. 1993; 329:1328-1334.
62. Goldstein FW, Papadopoulou B, Acar JF. The changing pattern of trimethoprim resistance in Paris, with a review of worldwide experience. Rev Infect Dis. 1986;8:725-737.
63. Gruneberg RN. Changes in urinary pathogens and their antibiotic sensitivities, 1971-1992. J Antimicrob Chemother. 1994;33(suppl A):1-8.
64. Gupta K, Scholes D, Stamm WE. Increasing prevalence of antimicrobial resistance among uropathogens causing acute uncomplicated cystitis in women. JAMA. 1999;281:736-738.
65. Martin JN, Rose DA, Hadley WK, PerdreauRemington F, Lam PK, Gerberding JL. Emergence of trimethoprim-sulfamethoxazole resistance in the AIDS era. J Infect Dis. 1999;180: 1809-1818.
66. Lepelletier D, Caroff N, Reynaud A, Richet H. Escherichia coli: epidemiology and analysis of risk factors for infections caused by resistant strains. Clin Infect Dis. 1999;29:548-552.
67. Steinke DT, Seaton RA, Phillips G, MacDonald TM, Davey PG. Factors associated with trimethoprim-resistant bacteria isolated from urine samples. J Antimicrob Chemother. 1999;43:841-843.
68. Wright SW, Wrenn KD, Haynes ML. Trimethoprim-sulfamethoxazole resistance among urinary coliform isolates. J Gen Intern Med. 1999; 14:606-609.
69. Zhanel GG, Karlowsky JA, Harding GKM, et al, for the Canadian Urinary Isolate Study Group. A Canadian national surveillance study of urinary tract isolates from outpatients: comparison of the activities of trimethoprim-sulfamethoxazole, ampicillin, mecillinam, nitrofurantoin, and ciprofloxacin. Antimicrob Agents Chemother. 2000; 44:1089-1092.
70. Sahm DF, Thornsberry C, Mayfield DC, Jones ME, Karlowsky JA. Multidrug-resistant urinary tract isolates of Escherichia coli: prevalence and patient demographics in the United States in 2000. Antimicrob Agents Chemother. 2001;45:1402-1406.
71. Huovinen P. Increases in rates of resistance to trimethoprim. Clin Infect Dis. 1997;24(suppl): S63-S66.
72. Manges AR, Johnson JR, Foxman B, O'Bryan TT, Fullerton KE, Riley LW. Widespread distribution of urinary tract infections caused by a multidrug-resistant Escherichia coli clonal group. N Engl J Med. 2001;345:1007-1013.
73. Gupta K, Hooten TM, Stamm WE. Increasing antimicrobial resistance and the management of uncomplicated community-acquired urinary tract infections. Ann Intern Med. 2001;135:41-50.
74. Warren JW, Abrutyn E, Hebel JR, Johnson JR, Schaeffer AJ, Stamm WE, for the Infectious Diseases Society of America. Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Clin Infect Dis. 1999;29:745-758.
75. Lipsky BA. Prostatitis and urinary tract infection in men: what's new; what's true? Am J Med. 1999;106:327-334.
76. Marchant C, Shurin PA. Antibacterial therapy for acute otitis media: a critical analysis. Rev Infect Dis. 1982;4:506-513.
77. Blumer JL, Bertino JS Jr, Husak MP. Comparison of cefaclor and trimethoprim-sulfamethoxazole in the treatment of acute otitis media. Pediatr Infect Dis. 1984;3:25-29.
78. Feldman W, Sutcliffe T, Dulberg C. Twice-daily antibiotics in the treatment of acute otitis media: trimethoprim-sulfamethoxazole versus amoxicillin-clavulanate. CMAJ. 1990;142:924-925.
79. Schwartz RH, Rodriguez WJ, Khan WN, Mann R, Barsanti RG, Ross S. Trimethoprim-sulfamethoxazole in the treatment of otitis media caused by ampicillin-resistant strains of Haemophilus influenzae. Rev Infect Dis. 1982;4:514-516.
80. Williams JW, Holleman DR, Samsa GP, Simel DL. Randomized controlled trial of 3 vs 10 days of trimethoprim/sulfamethoxazole for acute maxillary sinusitis. JAMA. 1995;273:1015-1021.
81. Renmarker K. A comparative trial of cotrimoxazole and doxycycline in the treatment of acute exacerbations of chronic bronchitis. Scand J Infect Dis. 1976;8:75-78.
82. Hughes DT. Single-blind comparative trial of trimethoprim-sulphamethoxazole and ampicillin in the treatment of exacerbations of chronic bronchitis. BMJ. 1969;4:470-473.
83. Pines A, Greenfield JS, Raafat H, Rahman M, Siddiqui AM. Preliminary experience with trimethoprim and sulphamethoxazole in the treatment of purulent chronic bronchitis. Postgrad Med J. 1969;45(suppl):89-90.
84. Anderson G, Williams L, Pardoe T, Peel ET. Cotrimoxazole versus cefaclor in acute on chronic bronchitis. J Antimicrob Chemother. 1981;8:487-489.
85. Hughes DT. The use of combinations of trimethoprim and sulphonamides in the treatment of chest infections. J Antimicrob Chemother. 1983; 12:423-434.
86. Gaskins JD, Holt RJ, Kyong CU, Weart CW, Ward J. Chemoprophylaxis of recurrent otitis media using trimethoprim/sulfamethoxazole. Drug Intell Clin Pharm. 1982;16:387-390.
87. Principi N, Marchisio P, Massironi E, Grasso RM, Filiberti G. Prophylaxis of recurrent acute otitis media and middle-ear effusion: comparison of amoxicillin with sulfamethoxazole and trimethoprim. AJDC. 1989;143:1414-1418 [published correction appears in AJDC. 1990;144:1180].
88. Niederman MS, Bass JB Jr, Campbell GD, et al, for the American Thoracic Society and the Medical Section of the American Lung Association. Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. Am Rev Respir Dis. 1993;148: 1418-1426.
89. Hoban DJ, Doern GV, Fluit AC, RousselDelvallez M, Jones RN. Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis. 2001;32(suppl):S81-S93.
90. Sinus and Allergy Health Partnership. Antimicrobial treatment guidelines for acute bacterial rhinosinusitis. Otolaryngol Head Neck Surg. 2000; 123(pt 2):S5-S31.
91. Niederman MS, Mandell LA, Anzueto A, et al, for the American Thoracic Society. Guidelines for the management of adults with community-acquired pneumonia: diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med. 2001;163:1730-1754.
92. Bartlett JG, Dowell SF, Mandell LA, File TM, Musher DM, Fine MJ. Practice guidelines for the management of community-acquired pneumonia in adults. Clin Infect Dis. 2000;31:347-382.
93. Ansdell VE, Ericsson CD. Prevention and empiric treatment of traveler's diarrhea. Med Clin North Am. 1999;83:945-973.
94. Murray BE. Resistance of Shigella, Salmonella, and other selected enteric pathogens to antimicrobial agents. Rev Infect Dis. 1986;8(suppl): S172-S181.
95. Ackers M-L, Puhr ND, Tauxe RV, Mintz ED. Laboratory-based surveillance of Salmonella serotype Typhi infections in the United States: antimicrobial resistance on the rise. JAMA. 2000; 283:2668-2673.
96. Bandres JC, Mathewson JJ, Ericsson CD, Dupont HL. Trimethoprim/sulfamethoxazole remains active against enterotoxigenic Escherichia coli and Shigella species in Guadalajara, Mexico. Am J Med Sci. 1992;303:289-291.
97. Hoge CW, Gambel JM, Srijan A, Pitarangsi C, Echeverria P. Trends in antibiotic resistance among diarrheal pathogens isolated in Thailand over 15 years. Clin Infect Dis. 1998;26:341-345.
98. Gutman LT, Wilfert CM, Quan T. Susceptibility of Yersinia enterocolitica to trimethoprim-sulfamethoxazole. J Infect Dis. 1973;128(suppl): S538.
99. Pastore G, Rizzo G, Fera G, Schiraldi O. Trimethoprim-sulphamethoxazole in the treatment of cholera: comparison with tetracycline and chloramphenicol. Chemotherapy. 1977;23:121-128.
100. Kuijper EJ, Peeters MF, Schoenmakers BS, Zanen HC. Antimicrobial susceptibility of sixty human fecal isolates of Aeromonas species. Eur J Clin Microbiol Infect Dis. 1989;8:248-250.
101. DuPont HL, Ericsson CD. Prevention and treatment of traveler's diarrhea. N Engl J Med. 1993;328:1821-1827.
102. Diekema DJ, Pfaller MA, Schmitz FJ, et al, and the SENTRY Participants Group. Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis. 2001;32(suppl):S114-S132.
103. Hoskins TW, Bernstein LS. Trimethoprim/sulphadiazine compared with penicillin V in the treatment of streptococcal throat infections. J Antimicrob Chemother. 1981;8:495-496.
104. Hughes WT, Feldman S, Chaudhary SC, Ossi MJ, Cox F, Sanyal SK. Comparison of pentamidine isethionate and trimethoprim-sulfamethoxazole in the treatment of Pneumocystis carinii pneumonia. J Pediatr. 1978;92:285-291.
105. Ruf B, Rohde I, Pohle HD. Efficacy of clindamycin/primaquine versus trimethoprim/sulfamethoxazole in primary treatment of Pneumocystis carinii pneumonia. Eur J Clin Microbiol Infect Dis. 1991;10:207-210.
106. Safrin S, Finkelstein DM, Feinberg J, et al, for the ACTG 108 Study Group. Comparison of three regimens for treatment of mild to moderate Pneumocystis carinii pneumonia in patients with AIDS: a double-blind, randomized, trial of oral trimethoprim-sulfamethoxazole, dapsone-trimethoprim, and clindamycin-primaquine. Ann Intern Med. 1996;124:792-802.
107. Toma E, Thorne A, Singer J, et al, for the CTN-PCP Study Group. Clindamycin with primaquine vs trimethoprim-sulfamethoxazole therapy for mild and moderately severe Pneumocystis carinii pneumonia in patients with AIDS: a multicenter, double-blind, randomized trial (CTN 004). Clin Infect Dis. 1998;27:524-530.
108. Kazanjian P, Locke AB, Hossler PA, et al. Pneumocystis carinii mutations associated with sulfa and sulfone prophylaxis failures in AIDS patients. AIDS. 1998;12:873-878.
109. Keystone JS, Kozarsky P. Isospora belli, Sarcocystis species, Blastocystis hominis, and Cyclospora. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and Practice of Infectious Diseases. 5th ed. Philadelphia, Pa: Churchill Livingstone Inc; 2000:2915-2920.
110. Bartlett JG. Medical Management of HIV Infection. Baltimore, Md: Johns Hopkins University; 1999.
111. Canessa A, Del Bono V, De Leo P, Piersantelli N, Terragna A. Cotrimoxazole therapy of Toxoplasma gondii encephalitis in AIDS patients. Eur J Clin Microbiol Infect Dis. 1992;11:125-130.
112. Torre D, Speranza F, Martegani R, Zeroli C, Banfi M, Airoldi M. A retrospective study of treatment of cerebral toxoplasmosis in AIDS patients with trimethoprim-sulphamethoxazole. J Infect. 1998; 37:15-18.
113. US Public Health Service (USPHS) and Infectious Diseases Society of America (IDSA). 1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. MMWR Recomm Rep. 1999;48(RR-10):1-59, 61-66.
114. Stein DS, Stevens RC, Terry D, et al. Use of low-dose trimethoprim-sulfamethoxazole thrice weekly for primary and secondary prophylaxis of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother. 1991;35:1705-1709.
115. Hardy WD, Feinberg J, Finkelstein DM, et al. A controlled trial of trimethoprim-sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome: AIDS Clinical Trials Group protocol 021. N Engl J Med. 1992;327:1842-1848.
116. Ioannidis JPA, Cappelleri JC, Skolnik PR, Lau J, Sacks HS. A meta-analysis of the relative efficacy and toxicity of Pneumocystis carinii prophylactic regimens. Arch Intern Med. 1996;156:177-188.
117. Carr A, Tindall B, Brew BJ, et al. Low-dose trimethoprim-sulfamethoxazole prophylaxis for toxoplasmic encephalitis in patients with AIDS. Ann Intern Med. 1992;117:106-111.
118. Anglaret X, Chene G, Attia A, et al. Early chemoprophylaxis with trimethoprim-sulphamethoxazole for HIV-1 infected adults in Abidjan, Cote d'lvoire: a randomised trial. Lancet. 1999;353: 1463-1468.
119. Wiktor SZ, Sassan-Morokro M, Grant AD, et al. Efficacy of trimethoprim-sulphamethoxazole prophylaxis to decrease morbidity and mortality in HIV-1-infected patients with tuberculosis in Abidjan, Cote d'lvoire: a randomised controlled trial. Lancet. 1999;353:1469-1475.
120. Buskin SE, Newcomer LM, Koutsky LA, Hooton TM, Spach DH, Hopkins SG. Effect of trimethoprim-sulfamethoxazole as Pneumocystis carinii pneumonia prophylaxis on bacterial illness, Pneumocystis carinii pneumonia, and death in persons with AIDS. J Acquir Immune Defic Syndr. 1999;20:201-206.
121. Fishman JA. Prevention of infection caused by Pneumocystis carinii in transplant patients. Clin Infect Dis. 2001;33:1397-1405.
122. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. MMWR Recomm Rep. 2000; 49(RR-10):1-125.
123. Kerr KG. The prophylaxis of bacterial infections in neutropenic patients. J Antimicrob Chemother, 1999;44:587-591.
124. Hughes WT, Armstrong D, Bodey GP, et al, for the Infectious Diseases Society of America. 2002 Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis. 2002;34:730-751.
125. Fass RJ, Barnishan J, Solomon MC, Ayers LW. In vitro activities of quinolones, β-lactams, tobramycin, and trimethoprim-sulfamethoxazole against nonfermentative gram-negative bacilli. Antimicrob Agents Chemother. 1996;40:1412-1418.
126. Gales AC, Jones RN, Forward KR, Liñares J, Sader HS, Verhoef J. Emerging importance of multi-drug resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients: geographic patterns, epidemiological features, and trends in the SENTRY Antimicrobial Surveillance Program (1997-1999). Clin Infect Dis. 2001;32(suppl):S104-S113.
127. Winslow DL, Pankey GA. In vitro activities of trimethoprim and sulfamethoxazole against Listeria monocytogenes. Antimicrob Agents Chemother. 1982;22:51-54.
128. Spitzer PG, Hammer SM, Karchmer AW. Treatment of Listeria monocytogenes infection with trimethoprim-sulfamethoxazole: case report and review of the literature. Rev Infect Dis. 1986;8: 427-430.
129. Meyer RD, Liu S. Determination of the effect of antimicrobics in combination against Listeria monocytogenes. Diagn Microbiol Infect Dis. 1987;6:199-206.
130. Lerner PI. Nocardiosis. Clin Infect Dis. 1996;22: 891-903.
131. Feurle GE, Marth T. An evaluation of antimicrobial treatment for Whipple's disease: tetracycline versus trimethoprim-sulfamethoxazole. Dig Dis Sci. 1994;39:1642-1648.
132. Durand DV, Lecomte C, Cathébras P, Rousset H, Godeau P, and the SNFMI Research Group on Whipple Disease. Whipple disease: clinical review of 52 cases. Medicine (Baltimore). 1997; 76:170-184.
133. Stegeman CA, Tervaert JW, de Jong PE, Kallenberg CGM. Trimethoprim-sulfamethoxazole (cotrimoxazole) for the prevention of relapses of Wegener's granulomatosis. N Engl J Med. 1996;335:16-20.
134. Red Book Updates. Montvale, NJ: Medical Economics Books; 2001.